Organ Care System (OCS) Liver
TransMedics, Inc. · Decision date Mar 9, 2026
What did the FDA approve?
FDA records P200031/S014 as a supplement to PMA P200031, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 9, 2026.
FDA approval order statement
the revised labeling that reflects the final results of the OCS Liver Perfusion (OLP) Registry post-approval study
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 9, 2026
- FDA change category
- Labeling Change - PAS
Regulatory record facts
- Identifier
- P200031/S014
- Regulatory pathway
- PMA supplement
- Applicant
- TransMedics, Inc.
- Product code
- QQK
- Decision code
- APPR
- Decision date
- Mar 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.
- Applicant
- TransMedics, Inc.
- Product code
- QQK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200031/S011 · Related supplement
Organ Care System (OCS) Liver
P200031/S012 · Related supplement
Organ Care System (OCS) Liver
P200031/S014 received
Application receipt date recorded by FDA.
P200031/S014 · FDA decision
Normal 180 Day Track No User Fee
P200031/S013 · Related supplement
Organ Care System (OCS) Liver
Timeline entries are records held by MedtechLedger for P200031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Organ Care System (OCS) LiverP200031/S011 | TransMedics, Inc. | PMA supplement | Oct 22, 2025 | FDA |
Organ Care System (OCS) LiverP200031/S012 | TransMedics, Inc. | PMA supplement | Dec 16, 2025 | FDA |
Organ Care System (OCS) LiverP200031/S013 | TransMedics, Inc. | PMA supplement | May 13, 2026 | FDA |
Explore the linked device profile
Other records with product code QQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
OrganOx metra SystemP200035/S038 | Organox Limited | PMA supplement | Oct 9, 2026 | FDA |
OrganOx metra SystemP200035/S041 | Organox Limited | PMA supplement | Aug 7, 2026 | FDA |
OrganOx metra SystemP200035/S040 | Organox Limited | PMA supplement | Jul 8, 2026 | FDA |
OrganOx metra SystemP200035/S037 | Organox Limited | PMA supplement | Jul 7, 2026 | FDA |
OrganOx metra SystemP200035/S039 | Organox Limited | PMA supplement | Jun 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
TransMedics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 200 Minuteman Rd., Suite 302, Andover, MA, 01810
Sources and methodology
- Original FDA record: P200031/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

